3SBio Inc represents a commitment to innovation, integrity, and excellence in the biopharmaceutical industry. The company values putting patients first and developing high-quality therapeutic solutions. With a focus on research and development, 3SBio Inc is dedicated to discovering, developing, and commercializing innovative biopharmaceutical products. The company's corporate philosophy centers around offering effective and affordable treatments to improve patients' lives. By staying true to their core values, 3SBio Inc aims to make a positive impact on healthcare and contribute to the well-being of individuals worldwide.

3SBio Inc is primarily present in China and the United States.

3SBio Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange in 2015, marking a major milestone in its history. Furthermore, 3SBio Inc has seen remarkable growth and success in the biopharmaceutical industry, particularly in the development and commercialization of innovative medicines. They have obtained regulatory approvals for various products, expanded their product portfolio, and established strategic partnerships to enhance their market presence. The company's dedication to research and development has also resulted in numerous scientific achievements and breakthroughs. Overall, 3SBio Inc has demonstrated consistent progress and remains a leading player in the biopharmaceutical sector.

3SBio Inc is a leading biotechnology company specializing in the research, development, and manufacturing of innovative biopharmaceutical products. Founded in 1993, the company has a rich history in the biotech industry. With its headquarters in China, 3SBio Inc has expanded globally and gained recognition for its expertise in therapeutic areas including nephrology, oncology, and immunology. The company is committed to improving patient outcomes through the development of high-quality, life-saving medications. 3SBio Inc has established itself as a trusted name in the biopharmaceutical sector, delivering innovative solutions to address unmet medical needs and improve the quality of life for patients worldwide.

The main competitors of 3SBio Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis International AG, Amgen Inc, and Roche Holding AG.

3SBio Inc is primarily active in the biotechnology and pharmaceutical industries.

3SBio Inc operates as a leading biotechnology company. The business model of 3SBio Inc revolves around the research, development, manufacturing, and commercialization of biopharmaceutical products. The company focuses on developing innovative therapies to address unmet medical needs, particularly in the fields of oncology, nephrology, and autoimmune diseases. By leveraging their expertise in biologics and in-house manufacturing capabilities, 3SBio Inc aims to deliver high-quality and affordable medicines to patients worldwide. With a commitment to advancing healthcare, 3SBio Inc continues to invest in R&D efforts and strategic partnerships, aiming to improve patient outcomes and enhance their market presence.

Pašreizējais KGV 3SBio nevar tikt aprēķināts.

KUV šobrīd 3SBio nevar aprēķināt.

AlleAktien kvalitātes vērtējums 3SBio ir 8/10.

Pašreiz nevar aprēķināt apgrozījumu 3SBio.

Pašlaik peļņa 3SBio nevar tikt aprēķināta.

The Chinese company 3SBio Inc is a leading company in the biopharmaceutical industry, specializing in the development, manufacturing, and marketing of biological drugs. 3SBio focuses on the areas of oncology, immunology, nephrology, and infectious diseases. The main products of 3SBio include biosimilars of innovative drugs such as rituximab, enoxaparin, adalimumab, darbepoetin alfa, pegaspargase, and etanercept. Biosimilars are biologically manufactured drugs that have similar active ingredients as original biologics and thus provide a more cost-effective alternative. 3SBio has the largest market share for biosimilars in China and continually expands its portfolio. In addition to biosimilars, 3SBio also offers innovative biological drugs. One example is Tpiao, a recombinant human thrombopoietin receptor agonist. It is used to treat thrombocytopenia in patients with hepatitis B or hepatitis C infections. Another important area for 3SBio is nephrology. The company has various products in its portfolio that are used to treat kidney diseases. These include, for example, the erythropoiesis-stimulating agent (ESA) ferumoxytol, which is used to treat iron deficiency anemia in chronic kidney disease, as well as binodenoson, an adenosine receptor agonist used for diagnostic imaging of kidney diseases. The business model of 3SBio Inc is based on the acquisition of promising technologies, its own research and development work, and the manufacturing and marketing of biological drugs. The company works closely with regulatory authorities and health organizations to achieve fast market approval for its products. An important aspect is also international distribution. 3SBio strategically enters growth markets in Asia, especially in China, and expands into other parts of the world. Through partnerships with other companies and the acquisition of firms in the biopharmaceutical industry, 3SBio continuously expands its value chain and its portfolio. Overall, 3SBio pursues a diversified business model based on the utilization of synergies in the areas of research, development, manufacturing, and marketing of biological drugs. By utilizing biosimilars and innovative active ingredients, the company has achieved high competitiveness and is on a path of expansion.

3SBio izmaksā dividendes 0 CNY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt 3SBio vai uzņēmums nedod dividendes.

3SBio ISIN ir KYG8875G1029.

3SBio WKN ir A14T7Q.

3SBio simbols ir 1530.HK.

Pēdējo 12 mēnešu laikā 3SBio maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos 3SBio plāno maksāt dividendes 0,11 CNY apmērā.

3SBio pašreizējā dividendu rentabilitāte ir .

3SBio maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos jūlijs, jūlijs, jūlijs, augusts.

3SBio pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,11 CNY. Tas atbilst dividendes ražībai 1,97 %.

3SBio tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu 3SBio apmērā 0,25 CNY, kas tika izmaksāta 5.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 22.07.2024..

Pēdējās dividendes izmaksa notika 5.08.2024..

Gadā 2023, 3SBio izmaksāja 0,2 CNY dividendes.

3SBio dividendes tiek izmaksātas CNY.